Alumis Inc 's

Name: Alumis Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ALMS Sales vs. its Competitors Q1 2026

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

<< ALMS Stock Performance Comparisons

<< See the full list of ALMS competitors

*Market share is calculated based on total revenue.

News about Alumis inc Contracts

Advancements in Systemic Lupus Erythematosus Treatment Unveiling the Efficacy of ESK-001, a Novel Oral TYK2 Inhibitor

November 14, 2024
: Systemic Lupus Erythematosus (SLE) poses a considerable challenge in rheumatology due to its heterogeneous nature and the varied response to treatments. Recent data presented at ACR Convergence 2024 by Alumis highlights ESK-001, a novel oral TYK2 inhibitor, demonstrating high-efficacy potential in the management of SLE. This article discusses the implications of these findings in the broader context of SLE treatment modalities and future directions for research.SLE is an autoimmune disorder characterized by widespread inflammation and tissue damage in affected organs. The increasing prevalence of SLE and its associated morbidity necessitate the development of innovative treatment strategies. Traditional t...

for theAlumis Soars into Q2 2024 Financial Success and a Leap into Psoriasis Treatment with ONWARD Clinical ...

August 13, 2024
Alumis Reports Promising Q2 2024 Financial Results and Marks Milestone with ESK-001 Phase 3 ONWARD Clinical Program for Psoriasis Alumis, a biotech leader known for its innovative therapies for chronic inflammatory diseases, recently announced its second quarter 2024 financial results and highlighted significant developments in its clinical pipeline and corporate achievements. The company’s focus on developing groundbreaking treatments to improve the quality of life for patients with serious conditions is evident in its latest advancements, particularly the initiation of patient dosing in its ESK-001 Phase 3 ONWARD clinical program for moderate-to-severe plaque psoriasis. Financial Performance Overview In ...

ALMS's Stock Performance relative to its Competitors

Publicly Traded Peers of Alumis inc

Sources: Alumis inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alumis inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.